-
Cidara Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results
-
Form SC 13D/A Cidara Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Cidara Therapeutics (CDTX) Announces $105 Million Private Placement
-
Cidara Therapeutics Announces $105 Million Private Placement
-
Cidara Therapeutics (CDTX) Announces Scientific Advisory Board with Infectious Disease Experts
-
Cidara Therapeutics Strengthens its Scientific Advisory Board with Infectious Disease Experts
-
Cidara Therapeutics Provides Corporate Update and Reports Second Quarter 2024 Financial Results
-
Form SC 13D Cidara Therapeutics, Filed by: RA CAPITAL MANAGEMENT, L.P.
-
Cidara Therapeutics Provides Corporate Update and Reports First Quarter 2024 Financial Results
-
Cidara Therapeutics Reacquires Global Development and Commercial Rights to CD388 and Announces Private Placement Financing of $240 Million
-
Expansion Therapeutics Raises $55.3 Million in Series A Financing to Advance Portfolio of Novel RNA Targeted Small Molecule Medicines to Treat Rare Diseases
-
Form SC 13G/A Cidara Therapeutics, Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13G/A Cidara Therapeutics, Filed by: RA CAPITAL MANAGEMENT, LLC
-
Form SC 13G Cidara Therapeutics, Filed by: RA CAPITAL MANAGEMENT, LLC

